2653-16-9

Basic information

• Product Name: 2-CHLORO-N-METHYL-N-(4-NITROPHENYL)ACETAMIDE
• Synonyms: 2-CHLORO-N-METHYL-N-(4-NITROPHENYL)ACETAMIDE;2-Chloro-N-methyl-4'-nitroacetanilide;Intedanib Impurity 11;Nintedanib intermediate
• CAS NO: 2653-16-9
• Molecular Formula: C₉H₉ClN₂O₃
• Molecular Weight: 228.63236
• Product Categories: Nintedanib;Intermediate of BIBF-1120 and PKI587
• Mol File: 2653-16-9.mol
• Article Data: 17

Chemical Properties

• Melting Point: 109.5-110 °C
• Boiling Point: 374.912°C at 760 mmHg
• Flash Point: 180.541°C
• Appearance: /
• Density: 1.392g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.606
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: Chloroform (Sparingly), DMSO (Sparingly), Methanol (Slightly)
• PKA: -4.02±0.50(Predicted)
• CAS DataBase Reference: 2-CHLORO-N-METHYL-N-(4-NITROPHENYL)ACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLORO-N-METHYL-N-(4-NITROPHENYL)ACETAMIDE(2653-16-9)
• EPA Substance Registry System: 2-CHLORO-N-METHYL-N-(4-NITROPHENYL)ACETAMIDE(2653-16-9)

Safety Data

• Hazardous Substances Data: 2653-16-9(Hazardous Substances Data)

Usage

Description

2-Chloro-N-methyl-N-(4-nitrophenyl)acetamide is an organic compound with the molecular formula C9H9ClN2O3. It is a derivative of acetamide, featuring a chloro and nitrophenyl group attached to the nitrogen atoms. 2-CHLORO-N-METHYL-N-(4-NITROPHENYL)ACETAMIDE is known for its potential applications in the synthesis of various pharmaceutical compounds.

Uses

Used in Pharmaceutical Industry:
2-Chloro-N-methyl-N-(4-nitrophenyl)acetamide is used as a reactant/reagent for the synthetic preparation of oxindole derivatives. These derivatives have been identified as inhibitors of tyrosine kinase, which are enzymes that play a crucial role in cell signaling and are often overactive in cancer cells. By inhibiting tyrosine kinase, these oxindole derivatives can potentially help in the development of targeted therapies for cancer treatment.

InChI:InChI=1/C9H9ClN2O3/c1-11(9(13)6-10)7-2-4-8(5-3-7)12(14)15/h2-5H,6H2,1H3

Upstream product

• 79-04-9 chloroacetyl chloride 
• 100-15-2 N-methyl(p-nitroaniline) 
• 586-78-7 para-nitrophenyl bromide 
• 541-88-8 Chloroacetic anhydride 
• 67-68-5 dimethyl sulfoxide 
• 17329-87-2 2-chloro-N-(4-nitro-phenyl)-acetamide 
• 77-78-1 dimethyl sulfate 
• 100-01-6 4-nitro-aniline 
• 4015-58-1 monochloroacetic acid anhydride 

Downstream Products

• 98589-93-6 1-methyl-6-nitro-1,2-dihydroquinoxalin-2-one 
• 1448363-12-9 2-azido-N-methyl-N-(4-nitrophenyl)acetamide 
• 262368-30-9 N-[(4-methyl-piperazin-1-yl)methylcarbonyl]-N-methyl-p-phenylendiamine 
• 1160294-26-7 nintedanib 
• 20870-91-1 5-amino-1-methyl-1,3-dihydro-2H-indol-2-one 

Relevant articles and documents

Indolone derivative and pharmaceutical application thereof

The invention provides an indolone derivative and pharmaceutical application thereof. The structure of the indolone derivative is shown as a formula (A). Experimental results show that the compound provided by the invention has obviously improved pharmacokinetic properties than BIBF1120, has excellent inhibition effects on VEGFR, FGFR and PDGFR, can be used as a VEGFR, FGFR and/or PDGFR inhibitor,an angiogenesis inhibitor and a drug for preventing and/or treating various tumors including pharyngeal squamous cell carcinoma, and has a wide application prospect.

INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS

The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring C, X1, X2, L1, R1, R2, R3, R4, R5, R6, R7, m and n are as defined herein, which are useful as MAP4K1 inhibitors, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment or prevention of various diseases, conditions and/or disorders mediated by MAP4K1.

Method for preparing Nintedanib,I intermediate through one-pot method

The invention relates to a method for preparing Nintedanib,I key intermediate N-(4-aminophenyl)-N-methyl-2-(4-methyl piperazine-1-group)acetamide through a one-pot method. The method comprises the steps that according to the technical scheme, N-methyl-4-nitroaniline is dissolved in an aqueous solution of an organic solvent and alkali, mixing is carried out, then chloroacetyl chloride or bromoacetyl bromide is dropwise added, and a first-stage reaction is carried out for 0.1-3 hours at the temperature of 0-70 DEG C; a water layer is removed, N-methyl piperazine is added, a second-stage reactionis carried out, and reacting is carried out for 2-10 hours at the temperature of 0-75 DEG C; then a reducing reagent is added, a third-stage reaction is carried out for 8-36 hours at the temperatureof 0-75 DEG C and the pressure of 15-100 psi. After the reaction is finished, filtering is carried out to remove the reducing reagent, the reaction liquid is condensed, a reverse phase solvent is added, crystallization is carried out, and the Nintedanib,I key intermediate N-(4-aminophenyl)-N-methyl-2-(4-methyl piperazine-1-group)acetamide (formula B) is obtained. According to the preparation method, the raw materials are easy to obtain, the process is simple, and the method is economical, environmentally friendly and suitable for industrial production.